ARTICLE | Company News
ODAC to review JNJ's Zarnestra
April 6, 2005 12:31 AM UTC
On May 5, FDA's Oncologic Drugs Advisory Committee will review an NDA from Johnson & Johnson (JNJ) for Zarnestra tipifarnib to treat newly diagnosed acute myeloid leukemia (AML) in patients 65 and old...